Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. ARIAD Pharmaceuticals was organised as a Delaware corporation in April 1991. The company is engaged in the
discovery and development of breakthrough medicines that regulate cell signalling with small molecules.
Dr David Baltimore, a founding member of ARIAD's Board of Scientific and Medical Advisors, and his colleagues
discovered NF-(kappa)B (NF-kB), a cellular protein that plays a critical role in cell-signalling pathways that regulate the
transcription of key genes involved in many major diseases, including cancer, atherosclerosis, asthma, arthritis,
diabetes, infectious disease, inflammatory bowel disease, rheumatoid arthritis, sepsis and stroke. ARIAD has
established what it believes to be a dominant NF-kB intellectual property position based on an exclusive licence to the
pioneering work of the Baltimore laboratory from Massachusetts Institute of Technology, The Whitehead Institute for
Biomedical Research and Harvard University.